Sensorium Therapeutics, which closed a $30 million Series A Tuesday, is embracing the complexity of neuropsychiatric diseases with nature-inspired psychoactive medicines.
https://www.pharmalive.com/wp-content/uploads/2022/11/DickSimon-Sensorium.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-11-08 10:08:382022-11-08 10:08:38Sensorium scores $30M to change risk-value proposition in CNS drug discovery
